Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1 Inhibitor, PD-L1 Inhibitor, CTLA-4 Inhibitor, Others), By Applications (Lung Cancer, Breast Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, Cervical Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Immune Checkpoint Inhibitors Market Size

The global immune checkpoint inhibitors market size was valued at USD 50.68 billion in 2025 and is projected to grow from USD 58.78 billion in 2026 to USD 192.58 billion by 2034, registering a CAGR of 15.99% during the forecast period from 2026 to 2034. North America dominated the immune checkpoint inhibitors market with a market share of 44.2% in 2025.

ICIs are a class of cancer immunotherapies that help the immune system recognize and attack cancer cells more effectively. Normally, immune checkpoints are regulators that prevent the immune system from attacking normal cells in the body. However, cancer cells can exploit these checkpoints to avoid detection by the immune system. ICIs work by blocking these checkpoints, allowing immune cells to identify and destroy cancer cells.

The major factors propelling the ICI market expansion are rising cancer cases, the availability of advanced screening technologies for early cancer detection, and the growing demand for effective cancer drugs. For instance, the World Health Organization (WHO) reported that 20 million new cancer cases were diagnosed in 2022, with lung, breast, and colorectal cancers accounting for 33.6% of the cases.

Additionally, expanding approvals and the increasing use of ICIs for various cancers, such as lung, melanoma, and cervical, are fueling demand in global healthcare settings. Moreover, the growing number of clinical trials for ICIs worldwide highlights the increasing interest in enhancing the therapeutic potential of these treatments.

The graph below depicts the number of ICI clinical trials for major locations.

Product Type Insights

The market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, and others. The PD-1 inhibitor segment leads the market due to its high efficacy in treating various cancers, such as non-small cell lung cancer, esophageal cancer, and melanoma, along with ongoing advancements in clinical trials and expanding indications for these therapies across global markets.

• For instance, in March 2024, BeiGene received U.S. Food and Drug Administration (FDA) approval for its PD-1 inhibitor TEVIMBRA (tislelizumab-jsgr) for the treatment of advanced/metastatic esophageal squamous cell carcinoma after prior treatment with chemotherapy.

Request Customizationto receive a tailored report.

Application Insights

The market is segmented into lung cancer, breast cancer, bladder cancer, melanoma, cervical cancer, colorectal cancer, Hodgkin lymphoma, and others. The lung cancer segment dominates the global market due to the high prevalence and mortality rates associated with the disease, making it a major focus for treatment advancements. Immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors such as pembrolizumab and nivolumab, have demonstrated significant efficacy in improving survival rates for patients with non-small cell lung cancer (NSCLC).

Additionally, the increasing adoption of these therapies as a first-line treatment and the growing number of approvals for ICIs in various lung cancer subtypes further contribute to the segment's dominance.

• For example, in January 2023, Merck & Co., Inc., announced that the FDA had approved KEYTRUDA, its anti-PD-1 therapy, as an adjuvant treatment for adult patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC) following surgery and platinum-based chemotherapy.

Indication Insights

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment holds a dominant position in the market, primarily due to their essential role in administering complex cancer therapies like ICIs. Hospitals serve as the primary centers for cancer treatment, where ICIs are frequently prescribed and closely monitored by specialized healthcare professionals.

Moreover, hospital pharmacies are equipped to ensure the proper storage and handling of these biological drugs, which often require stringent conditions to maintain their efficacy. They also provide comprehensive patient support, including education on treatment protocols and management of side effects.

This combination of factors significantly enhances the market share of hospital pharmacies in the distribution of ICIs, solidifying their critical role in delivering effective cancer therapies.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America holds a dominant position in the ICI market, with 55.50% market share accounting for the largest revenue share. This leadership can be attributed to several key factors, including a well-established healthcare infrastructure, substantial investments in research and development, and a high prevalence of cancer. The presence of major industry players such as Bristol-Myers Squibb Company, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc., alongside favorable regulatory support, further enhances the market’s growth potential in the region.

U.s. Immune Checkpoint Inhibitors Market Trends

• U.S. – The U.S. continues to lead the ICI market due to its robust healthcare system and substantial investment in cancer research. The high prevalence of cancer cases further drives the demand for advanced therapies. For instance, the National Cancer Institute projects that 2,001,140 new cancer cases will be diagnosed in the U.S. in 2024, with the number expected to rise to 29.9 million by 2040. Additionally, strong support from regulatory agencies such as the U.S. FDA expedites the approval of novel treatments, enhancing patient access to these advanced therapies.
• Canada - In Canada, the strong emphasis on personalized medicine and precision oncology significantly propels market growth. The Canadian healthcare system prioritizes access to cutting-edge cancer therapies, and increasing public and private funding for cancer research fosters innovation. Moreover, the growing prevalence of cancer, combined with supportive regulatory policies, enhances the adoption of ICIs, establishing Canada as a key market for these therapies.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Immune Checkpoint Inhibitors Market Trends

The Asia-Pacific region is projected to experience the fastest compound annual growth rate (CAGR) during the forecast period. This rapid growth is driven by increasing cancer incidence, heightened awareness of advanced cancer therapies, and growing investments in healthcare infrastructure across countries like China, Japan, and India.

Additionally, improving regulatory frameworks and an increase in partnerships between local and global pharmaceutical companies are facilitating greater access to ICI treatments, contributing to the region's rapid market expansion. These dynamics position the Asia-Pacific region as a key area of growth in the global ICI market.

• China - In China, a rapid increase in cancer incidence is the major driver in the ICI market. The country faces significant public health challenges due to the high burden of cancer cases, prompting increased investments in oncology research and drug development. For instance, according to the World Health Organization (WHO) 2023, 48,24,703 new cancer cases were reported in 2022.
• India - In India, the increasing incidence of cancer and rising awareness of advanced treatment options drive the demand for ICIs. The growing emphasis on improving healthcare infrastructure, coupled with government initiatives to enhance cancer care, creates a favorable environment for the ICI market. Moreover, the influx of foreign investments in India's biotechnology sector stimulates research and development activities, further propelling the market's growth.
• Australia - In Australia, the increasing incidence of cancer and a strong commitment to advancing cancer care drive the market. The Australian healthcare system supports access to innovative therapies, with strong government initiatives promoting research and development in oncology. Moreover, the collaboration between academic institutions and pharmaceutical companies fosters the development of new ICIs, enhancing the market's growth potential.

Europe Immune Checkpoint Inhibitors Market Trends

• Germany – Germany's well-established healthcare system and commitment to medical innovation are key drivers for the ICI market. The country is known for its high standards of patient care and a strong focus on research and development in oncology. Moreover, the increasing incidence of cancer and growing awareness of ICIs among healthcare professionals contribute to growth, supported by favorable reimbursement policies for innovative cancer therapies.
• UK - The United Kingdom's National Health Service (NHS) plays a significant role in driving the market growth. The NHS's commitment to providing access to innovative cancer therapies supports the integration of ICIs into standard treatment protocols. Moreover, ongoing clinical trials and research collaborations between academic institutions and pharmaceutical companies contribute to the development of new ICI therapies, enhancing the country's position in the global market.
• France - In France, the government's commitment to improving cancer care and increasing funding for oncology research drives the ICI market. The French healthcare system emphasizes the integration of innovative therapies into treatment protocols, enhancing patients' access to ICIs. Moreover, strong collaboration between pharmaceutical companies and academic institutions fosters the development of new ICI therapies, further supporting market expansion.

Company Market Share

Key players in the immune checkpoint inhibitors market are pursuing strategic collaborations, acquisitions, and partnerships to enhance their product offerings and broaden their market reach.

Immutep Ltd: An emerging provider: Immutep Ltd is an emerging player in the market, known for its innovative LAG-3 immunotherapies, which target a novel checkpoint pathway, positioning the company as a key player in advancing next-generation cancer treatments.

Recent Development

• In September 2024, Immutep Ltd. announced topline results from the TACTI-003 Phase IIb trial evaluating eftilagimod alfa (efti) in combination with Merck & Co., Inc., anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC).

List of Key and Emerging Players in Immune Checkpoint Inhibitors Market